Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.47 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27740328 | 0.81 | SLC6A4 (0.54) | SLC6A4SIGMAR1TAAR1SLC18A2CYP2D6 | |
| SCHEMBL4214716 | 0.76 | GAA (0.69) | CHRM1KDM1ACYP2D6 | |
| SCHEMBL28219352 | 0.75 | SIGMAR1 (0.50) | SLC6A4SIGMAR1TAAR1SLC18A2KDM1A | |
| SCHEMBL20061130 | 0.73 | SIGMAR1 (0.56) | SLC6A4SIGMAR1TAAR1SLC18A2CYP2D6 | |
| SCHEMBL8081164 | 0.73 | ACHE (0.68) | — | |
| SCHEMBL20061148 | 0.73 | SIGMAR1 (0.56) | SLC6A4SIGMAR1TAAR1SLC18A2CYP2D6 | |
| SCHEMBL6482992 | 0.73 | SLC6A4 (0.49) | SLC6A4SIGMAR1TAAR1SLC18A2 | |
| SCHEMBL27589444 | 0.73 | SLC6A4 (0.49) | SLC6A4SIGMAR1TAAR1SLC18A2 | |
| SCHEMBL27589646 | 0.73 | SLC6A4 (0.49) | SLC6A4SIGMAR1TAAR1SLC18A2 | |
| SCHEMBL6494537 | 0.73 | SLC6A4 (0.49) | SLC6A4SIGMAR1TAAR1SLC18A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | SLC6A4 4795/4885SIGMAR1 4101/4885HSD17B10 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.